Items of recent pandemic news you may have missed: How to get the most out of home rapid testing; new evidence that breakthroughs don’t transmit much; a new WHO committee to investigate virus origins; and more. Plus a frippery. A … Continue reading →
Items of recent pandemic news: Saliva tests may not be sensitive enough for the asymptomatic; early antiviral promise for a cholesterol-lowering drug; booster shots coming to the immunocompromised and then to all US citizens; and more. Plus a frippery. 1. … Continue reading →
Items of recent pandemic news you may have missed: Moderna kids’ trial is enrolling; a new variant seen in Polish mink; a rapid-testing approach to in-person schooling; the tidal wave of vaccine mandates; and more. Plus a frippery. 1. Vaccination … Continue reading →
Items of recent pandemic news you may have missed: Too much testing of asymptomatic immune people? The new risk calculus of the delta variant, the coming mitigations, the anatomy of why delta spreads so fast, and more. Plus a frippery. … Continue reading →
Nine items of recent pandemic news you may have missed: Rapid testing, mixing and matching vaccines, booster shots, the genetics predicting severe Covid-19, another blow to J&J, some mechanisms behind neurological damage, and more. Plus a frippery. 1. Pfizer wants … Continue reading →
This week the Update moves from its former strictly biweekly cadence to a weekly format; each issue will encompass a larger number of brief items. There may occasionally be longer features. Fear not, the frippery is here to stay. mRNA … Continue reading →
Belatedly, three items of recent pandemic news: Novavax and the EU; a detailed study of long haulers in the VA health care system; and the imminent authorization of Pfizer’s vaccine for young adolescents. Plus news briefs and a frippery. Authorization … Continue reading →
Herewith three items of pandemic news: the UK variant seems to spread faster in the young; what’s next in vaccines (by new contributor Doug Pardee); and the import of the PCR test cycle threshold. Plus the accustomed frippery. Cycle threshold … Continue reading →
Herewith three items of pandemic news you may have missed recently: How wearable computers could predict Covid-19; the complicated situation with autoantibodies; and the late-stage trial of German company CureVac’s vaccine candidate. Plus the accustomed frippery. CureVac’s candidate enters Phase … Continue reading →
Herewith three items of pandemic news you may have missed recently: Covid tests you should not use; all about dry ice; and the imminence of shots going into arms. Plus a frippery. Vaccinations should start soon In England, regulators are … Continue reading →
Herewith three items of pandemic news you may have missed recently: mental health associations with Covid-19; an anti-depressant possibly protective against worsening disease; and using testing to shorten the time of quarantine. Plus the usual frippery. OCD drug fluvoxamine may … Continue reading →
Herewith three items of pandemic news you may have missed recently: testing a thyroid hormone for Covid-ARDS; grocery store clerks at high risk; and a simulator for rapid testing scenarios. Plus a frippery. A dashboard for exploring rapid testing Perhaps … Continue reading →
Herewith three items of pandemic news you may have missed recently: Using artificial intelligence to diagnose asymptomatic Covid-19; Medicare will pay for an EUA’ed vaccine; and how obesity may complicate vaccination. Plus a pair of fripperies. Cough twice into the … Continue reading →
Today we offer four items of Covid-19 news: a county-level dashboard of dangerousness; new discoveries on how the virus spreads so effectively and why it inhibits long-term immunity; and at-home saliva testing. Plus the accustomed frippery. Why illness may not … Continue reading →
Herewith three items of Covid-19 news you may have missed this week: viral loads are falling; glasses might help; and dogs sniff for Covid. Plus the accustomed frippery. Viral loads are falling ICU admissions and death rates from Covid-19 have … Continue reading →
